{"id":"W4417023476","doi":"10.1182/blood-2025-5574","title":"INCB057643, a bromodomain and extra-terminal protein inhibitor, in combination with ruxolitinib in patients with myelofibrosis: A phase 1 study of safety and efficacy","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ruxolitinib; Myelofibrosis; Tolerability; Anemia; Myeloproliferative neoplasm; Bromodomain; Phases of clinical research; Phlebotomy; Adverse effect","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001794251,0.0009552917,0.001698879,0.0004148135,0.000302588,0.0009204439,0.0006532724,0.0009225229,0.002127027],"category_scores_gemma":[0.0007277133,0.000448965,0.001204493,0.0004260442,0.000621063,0.0006337464,0.0002901428,0.002345362,0.0005184992],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007842534,"about_ca_system_score_gemma":0.001056853,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004705337,"about_ca_topic_score_gemma":0.001401631,"domain_scores_codex":[0.9994777,0.0002643196,0.00003208989,0.00008263044,0.0000703675,0.00007294698],"domain_scores_gemma":[0.9994074,0.000117425,0.0001514419,0.00004579985,0.00003968511,0.0002382388],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6340152,0.07846978,0.01141795,0.001508287,0.002966394,0.000540479,0.0003761981,0.003529622,0.07397791,0.0003482004,0.003236622,0.1896134],"study_design_scores_gemma":[0.3836716,0.5798184,0.02152384,0.00007107302,0.001020849,0.0007184464,0.00007266284,0.002405347,0.007479431,0.0001542099,0.003014152,0.00005007555],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9922649,0.004971225,0.0003313178,0.0002590526,0.00005400223,0.0006291736,0.0004651984,0.00005190032,0.0009731852],"genre_scores_gemma":[0.9944534,0.001899398,0.001006778,0.0004306717,0.00009487491,0.0004497053,0.0007895468,0.00001138871,0.0008641904],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002127027,"threshold_uncertainty_score":0.009489,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.00700897888615926,"score_gpt":0.2553300017353423,"score_spread":0.2483210228491831,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}